Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80


p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

Banerjee A, Koziol-White C, Panettieri R Jr.

Curr Opin Pharmacol. 2012 Jun;12(3):287-92. doi: 10.1016/j.coph.2012.01.016. Epub 2012 Feb 24. Review.


Tristetraprolin and its role in regulation of airway inflammation.

Prabhala P, Ammit AJ.

Mol Pharmacol. 2015 Apr;87(4):629-38. doi: 10.1124/mol.114.095984. Epub 2014 Nov 26. Review.


Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease.

Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E, Strauch J, Koch A.

J Pharmacol Exp Ther. 2010 Dec;335(3):788-98. doi: 10.1124/jpet.110.166843. Epub 2010 Aug 26.


Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.

Terajima M, Inoue T, Magari K, Yamazaki H, Higashi Y, Mizuhara H.

Eur J Pharmacol. 2013 Jan 5;698(1-3):455-62. doi: 10.1016/j.ejphar.2012.11.021. Epub 2012 Nov 23.


Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.

Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad el-B, Barnes PJ, Newton R.

Mol Pharmacol. 2006 Aug;70(2):697-705. Epub 2006 May 10.


Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D.

J Pharmacol Exp Ther. 2011 Sep;338(3):732-40. doi: 10.1124/jpet.111.180737. Epub 2011 May 24.


Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.

Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 4;10:283-91. doi: 10.2147/COPD.S72403. eCollection 2015.


Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.

Raidl M, Sibbing B, Strauch J, Müller K, Nemat A, Schneider PM, Hag H, Erdmann E, Koch A.

Cell Biochem Biophys. 2007;49(2):98-110.


Progress towards the development of anti-inflammatory inhibitors of IKKbeta.

Bamborough P, Callahan JF, Christopher JA, Kerns JK, Liddle J, Miller DD, Morse MA, Rumsey WL, Williamson R.

Curr Top Med Chem. 2009;9(7):623-39. Review.


A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients.

Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R.

J Clin Pharmacol. 2010 Jan;50(1):94-100. doi: 10.1177/0091270009347873. Epub 2009 Oct 30.


Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.

Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L, Kragballe K.

Br J Dermatol. 2010 Dec;163(6):1194-204. doi: 10.1111/j.1365-2133.2010.10036.x.


Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases.

Chopra P, Kanoje V, Semwal A, Ray A.

Expert Opin Investig Drugs. 2008 Oct;17(10):1411-25. doi: 10.1517/13543784.17.10.1411 . Review.


Kinase inhibitors and airway inflammation.

Adcock IM, Chung KF, Caramori G, Ito K.

Eur J Pharmacol. 2006 Mar 8;533(1-3):118-32. Epub 2006 Feb 8. Review. Retraction in: Eur J Pharmacol. 2012 May 15;683(1-3):340.


Frontrunners in novel pharmacotherapy of COPD.

Barnes PJ.

Curr Opin Pharmacol. 2008 Jun;8(3):300-7. doi: 10.1016/j.coph.2008.03.001. Epub 2008 May 3. Review.


Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, Barnes PJ.

J Pharmacol Exp Ther. 2007 May;321(2):734-42. Epub 2007 Feb 22.


DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.

Kang JS, Kim HM, Choi IY, Han SB, Yoon YD, Lee H, Park KH, Cho IJ, Lee CW, Lee K, Lee KH, Park SK.

J Pharmacol Exp Ther. 2010 Aug;334(2):657-64. doi: 10.1124/jpet.109.161687. Epub 2010 Apr 28.


New therapies for chronic obstructive pulmonary disease.

Barnes PJ.

Med Princ Pract. 2010;19(5):330-8. doi: 10.1159/000316368. Epub 2010 Jul 14. Review.


Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.

Grund EM, Kagan D, Tran CA, Zeitvogel A, Starzinski-Powitz A, Nataraja S, Palmer SS.

Mol Pharmacol. 2008 May;73(5):1394-404. doi: 10.1124/mol.107.042176. Epub 2008 Feb 5.

Supplemental Content

Support Center